glp-1 news today 2025-10-16 2025 october 16 The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients FDA takes aim at telehealth

Inject slowly to reduce tissue trauma

Building on this initial imaging success, the National Institutes of Health (NIH) awarded a major grant for an ongoing randomized, double-blind, placebo-controlled clinical trial (NCT04542161) exploring much higher dosages of up to 3,600 mg/day of NAC

IV glutathione use has been linked to serious adverse effects such as liver failure, kidney failure, and Stevens-Johnson syndrome, calling into question its safety

doi: 10.3390/jcm12051948 160 WangH.AiniwaerA.SongY.QinL.PengA.BaoH.et al

A 30 mg tirzepatide vial with 3 mL of bacteriostatic water makes 10 mg/mL, where 5 mg draws 50 units and 10 mg draws 100 units

The tricky part is that extra pounds cause more enzymes to build up